

What threats and opportunities are shaping the future of the generic drugs market?

- > THE WORLD GENERIC MARKET REPORT 2007
- > A wealth of market, company and product intelligence on this rapidly evolving industry!
- >
- > The fifth edition of this respected report presents a detailed picture of the nature and state of the world market for generic pharmaceuticals as of November 2006 and includes market forecasts to 2011.
- >
- > THE CHANGING FACE OF THE GENERICS INDUSTRY
- > The pace of corporate consolidation grows ever faster. Nine acquisitions were announced in 2006 including well known companies such as Andrx and Pliva. Increasingly the industry is being rationalised and dominated by fewer and fewer larger players. Teva and Sandoz may be fighting it out for the top spot but the speed of change is seeing the corporate landscape change continuously.
- >
- > EMERGING MARKETS TO 2011
- > Established generic markets may currently account for the bulk of generic prescribing and value, but where is the industry going in the future? In terms of growth not one of the leading markets features, but look to France, Spain, Brazil and Italy if you want significant double digit growth to 2011.
- >
- > KEY COMPANY, MARKET AND PRODUCT INFORMATION
- > To understand the generic market, Espicom, the publisher of the respected twice-monthly business publication World Generic Markets, has published The World Generic Market Report 2007. Packed with facts, figures, analysis and statistics, the 480+ page report provides the most thorough report available on generic markets, products and companies and the issues they face.
- >
- > INDUSTRY CONSOLIDATION, EMERGING GENERIC MARKETS, BIOSIMILARS PLUS MUCH, MUCH MORE...
- > Published in November 2006, this report draws on primary research with companies, statistics offices, health ministries and trade associations worldwide and provides standard, comparative data and discussion on key issues such as:
- >
- > Industry consolidation and the emergence of “super” generic companies

- > Double digit generic market growth – but where?
- > Biosimilars: now live in Europe – but elsewhere?
- > Authorised generics and other 180-day exclusivity issues in the US
- > Key legal challenges
- > The political and funding background
- > Intellectual property issues
- >
- > REPORT CONTENTS
- >
- > Global Overview
- > Industry consolidation
- > Current issues in the USA
- > The widening influence of India
- > WTO Agreement
- > Biosimilars
- > Current issues in the European Union
- > Prospects for growth
- >
- > Country Market Data Covering:
- > Key facts
- > Generic market value and 5-year forecast
- > Patent protection/IP
- > Pricing/reimbursement
- >
- > Countries Covered:
- > Australia
- > Brazil
- > Canada
- > France
- > Germany
- > India
- > Italy
- > Japan
- > Netherlands
- > South Africa
- > Spain
- > Switzerland
- > UK
- > USA
- >
- > Company Data Covering:
- > Financial performance
- > ANDAs and launched products
- > M&A activity and litigation
- >
- > Companies Covered:

- > Apotex
- > Aspen Pharmacare
- > Barr Laboratories
- > Cipla
- > Dr Reddy's
- > EGIS
- > Hospira
- > KRKA
- > Lannett
- > Mayne Pharma
- > Merck Generics
- > Mylan Labs
- > Par Pharmaceuticals
- > Perrigo
- > Pliva
- > Ranbaxy
- > ratiopharm
- > Gedeon Richter
- > Sandoz
- > Sawai
- > Stada Arzneimittel
- > Teva Pharmaceutical Industries
- > Towa Pharmaceuticals
- > Watson Pharmaceuticals
- > Winthrop
- > Wockhardt
- > Zentiva
- > Zydus Cadila
- >
- > The World Generic Market Report 2007 is available now in print and Adobe
- > Acrobat pdf via email editions for just US\$1195/£595/€1070 per copy.
- >
- > TO ORDER YOUR COPY TODAY GO TO:
- >
- > <http://www.espicom.com/prodcat.nsf/structure/SourceLanding?EditDocument&Referer=FR03EF&ProductCode=00000011>
- >
- >
- > Regards,
- >
- > Ian Taylor
- > Editorial Director
- >
- >
- > We hope you enjoy receiving this information from Espicom
- > Business

> Intelligence and you are welcome to forward this email to your friends
> and
> colleagues. Anyone who wishes to benefit from this service should go
> to
> our registration page:
> <http://www.espicom.com/web.nsf/structure/frmMktRegHF?OpenDocument>
>
> If, however, you do not wish to receive future issues, please reply to
> this
> message, typing 'no thanks' in the subject box of your email.
>
>
>

=====
=====

>
> Espicom Limited
> Registered Office: Lincoln House, City Fields Business Park, City Fields
> Way, Chichester, West Sussex, PO20 2FS, UK.
> Tel +44 (0)1243 533322 Fax +44 (0)1243 533418 Sales_Desk@espicom.com
> Company Registration No. 2768600
>
> Espicom USA Inc., 116 Village Boulevard, Princeton Forrestal Village,
> Princeton, NJ 08540-5799, USA.
> Tel: +1 (609) 951 2227 Fax +1 (609) 734 7428 USA_SalesDesk@espicom.com
> Registered Office: 600 College Road East, Princeton, New Jersey 08540,
> USA.
> Taxpayer Identification No. 22-3561984
>
